SMMTSummit Therapeutics Inc.
$17.60-6.9% 1Y
$17.60
$12.4252 weeks$26.38
SMMT in its own filings
Nothing in SMMT's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
336
Events found in the filings · across 555 filings · the record starts in 2014
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 29, 2026
Most recent filing · Form 8-K
- Record starts
- Dec 31, 2014
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Oct 19, 2026
- Change in certifying accountanthistorical
- 2021-05-26
- Security removed from listing or deregisteredhistorical · usually a matured note or preferred class, not the common shares
- 2020-09-18
- SEC comment-letter activity26 occurrences
- 2025-01-21
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 29, 2026On September 28, 2026, Summit Therapeutics Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with AstraZeneca Holdings B.V. (the “Investor”), a subsidiary of AstraZeneca plc, for the issuance and sale by the Company of 108,955.3686 shares (the “Preferred Shares”) of the …Material agreement entered · Form 8-K
- Sep 15, 2026On September 15, 2026, Summit Therapeutics Inc. (the "Company") issued a press release announcing that updated overall survival results from the global Phase III HARMONi clinical trial were presented today at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer (“WCLC 2026”)Other event · Form 8-K
- Sep 14, 2026On September 13, 2026, Summit Therapeutics Inc. issued a press release noting that its partner, Akeso Inc., announced that updated data, including overall survival, from the randomized, double-blind Phase III HARMONi-2 trial, is being presented at the International Association for the Study of Lung Cancer’s 2026 World …Other event · Form 8-K
- Sep 3, 2026On September 2, 2026, Summit Therapeutics Inc. issued a press release noting that its partner, Akeso Inc., (“Akeso”) announced positive overall survival (“OS”) results from the randomized, double-blind Phase III HARMONi-2 study evaluating ivonescimab monotherapy against pembrolizumab monotherapy in patients with …Other event · Form 8-K
- Aug 26, 2026On August 25, 2026, Summit Therapeutics Inc. issued a press release noting that its partner, Akeso, Inc., (“Akeso”) announced positive topline results from the randomized Phase III HARMONi-GI1 study (“HARMONi-GI1”) evaluating ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line …Other event · Form 8-K
- Aug 5, 2026On August 5, 2026, Summit Therapeutics Inc. issued a press release announcing the expansion of its global registration-enabling clinical development program for ivonescimab into urothelial carcinoma, or bladder cancer, with the planned initiation of the global, multi-regional Phase II/III HARMONi-GU1 trial …Other event · Form 8-K
- Jul 23, 2026On July 23, 2026, Summit Therapeutics Inc. (the “Company”) entered into a distribution agreement (the “Distribution Agreement”) with J.P. Morgan Securities LLC (“Sales Agent”), as sales agent, pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares of the Company’s common …Material agreement entered · Form 8-K
- Jul 22, 2026On July 22, 2026, Summit Therapeutics Inc. (the “Company”) issued a press release announcing results of an updated overall survival (“OS”) analysis from the Phase III HARMONi clinical trial (“HARMONi”)Other event · Form 8-K
- Jun 3, 2026On June 2, 2026, the Audit Committee and all independent directors of the Board of Directors of Summit Therapeutics Inc. (the “Company”) approved one or more Company affiliates to purchase shares of the Company’s common stock under the previously disclosed at-the-market offering with JP Morgan Securities LLC acting as …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…